Calithera Biosciences, Inc. (CALA)
CALA Price and Sentiment
CALA Latest news
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q3 2021 Results - Earnings Call Transcript2021-11-09 21:35
Calithera Biosciences, Inc. (CALA) CEO Susan Molineaux on Q3 2021 Results - Earnings Call Transcript
-- Company strengthened precision oncology clinical pipeline through acquisition of mTORC 1/2 inhibitor sapanisertib and SYK inhibitor mivavotinib from Takeda Pharmaceuticals -- -- Cash, cash equivalents and investments totaled $84.5 million as of September 30, 2021 --
Calithera Biosciences Inc (NASDAQ: CALA) has decided to terminate its phase 2 KEAPSAKE trial based on a lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis. The Phase 2 KEAPSAKE study was designed to evaluate the safety and anti-tumor activity of telaglenastat plus standard-of-care chemo-immunotherapy as front-line therapy for stage IV non-squamous non-small cell lung cancer (NSCLC) harboring KEAP1 or NRF2 mutation.
-- Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of Directors -- Dr. Kuriakose to succeed Keith Orford, MD, PhD, who will assume seat on Calithera Board of Directors
--KEAPSAKE interim analysis demonstrated lack of clinical benefit among patients treated with telaglenastat
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the Company's third quarter 2021 financial results will be released on Tuesday, November 9, 2021. Company management will host a conference call on Tuesday, November 9, 2021 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights.
Calithera Biosciences Inc (NASDAQ: CALA) shared interim safety and efficacy results from a Phase 1b trial evaluating CB-280, the company's investigational arginase inhibitor, in adults with cystic fibrosis (CF). The data were shared at the North American Cystic Fibrosis Foundation Conference (NACFC).
Calithera Presents Interim Data from Phase 1b Trial of Arginase Inhibitor CB-280 in Cystic Fibrosis at NACFC 20212021-11-01 07:00
-- CB-280 was well-tolerated, showed linear PK and demonstrated robust dose-related PD effects -- Encouraging trends seen in disease biomarkers including increased FeNO and decreased sweat chloride -- Early positive trend seen in FEV1, a safety endpoint
Calithera Biosciences to Present First Clinical Data from Development Program for Arginase Inhibitor CB-280 at NACFC 20212021-10-21 08:00
SOUTH SAN FRANCISCO, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage biopharmaceutical company, today announced that data from its Phase 1b trial of CB-280, the company's investigational arginase inhibitor for the treatment of cystic fibrosis (CF), will be shared in a poster presentation at the North American Cystic Fibrosis Conference (NACFC), taking place virtually November 2-5, 2021.
Calithera Biosciences Inc (NASDAQ: CALA) has agreed to acquire two clinical-stage cancer-focused compounds from Takeda Pharmaceutical Company Limited (NYSE: TAK). The transaction terms include a total upfront cash payment to Takeda of $10 million and $35 million in Calithera Series A preferred stock.